|
diabetes |
18 |
|
myocardial ischemia injury |
11 |
|
adiponectin |
10 |
|
biology |
10 |
|
diabetic cardiomyopathy |
9 |
|
ischemia reperfusion injury |
9 |
|
oxidative stress |
9 |
|
protein kinase cβ |
9 |
|
antioxidants |
8 |
|
apoptosis |
8 |
|
bioinformatics |
8 |
|
jak2/stat3 |
8 |
|
pi3k/akt |
8 |
|
diabetes mellitus |
7 |
|
propofol |
7 |
|
cardioprotection |
6 |
|
caveolin-3 |
6 |
|
humans |
6 |
|
insulin resistance |
6 |
|
myocardial ischaemia/reperfusion |
6 |
|
remifentanil |
6 |
|
acetylcysteine - pharmacology - therapeutic use |
5 |
|
adipocyte fatty-acid-binding protein |
5 |
|
adiponectin - biosynthesis - metabolism |
5 |
|
allopurinol - pharmacology - therapeutic use |
5 |
|
antioxidants - pharmacology - therapeutic use |
5 |
|
bile acids |
5 |
|
cardiac dysfunction |
5 |
|
cholesterol homeostasis |
5 |
|
cyp7a1 |
5 |
|
diabetes complications - drug therapy - metabolism - pathology - physiopathology |
5 |
|
endothelial nitric oxide synthase/nitric oxide (enos/no) pathway |
5 |
|
ep4 |
5 |
|
exercise responsiveness |
5 |
|
glucose dysregulation |
5 |
|
glycogen synthase kinase |
5 |
|
gut microbiota |
5 |
|
heme oxygenase-1 |
5 |
|
hypercholesterolemia |
5 |
|
infarct size |
5 |
|
ischaemic heart disease |
5 |
|
janus-activated kinase |
5 |
|
left ventricular hypertrophy |
5 |
|
microarray |
5 |
|
microrna |
5 |
|
myocardial hypertrophy and dysfunction |
5 |
|
myocardial ischaemia/reperfusion injury |
5 |
|
nrf2 |
5 |
|
personalized medicine |
5 |
|
proteomics |
5 |
|
regulatory network |
5 |
|
ruboxistaurin |
5 |
|
signal transducer and activator of transcription 3 |
5 |
|
anaesthesiology |
4 |
|
animals |
4 |
|
autophagy |
4 |
|
bioavailability |
4 |
|
biochemical genetics |
4 |
|
brg1 |
4 |
|
cell type-specific |
4 |
|
databases - nucleic acid |
4 |
|
disease models, animal |
4 |
|
disease-susceptible gene |
4 |
|
dose-response relationship, drug |
4 |
|
epigenome |
4 |
|
genetic loci |
4 |
|
genetic variation |
4 |
|
genotype-phenotype correlations |
4 |
|
heterozygote |
4 |
|
hif-1a |
4 |
|
inos |
4 |
|
internet |
4 |
|
ischaemia/reperfusion injury |
4 |
|
isoflurane postconditioning |
4 |
|
m2 macrophage polarization |
4 |
|
male |
4 |
|
mapping complex traits |
4 |
|
medical sciences |
4 |
|
mutation detection |
4 |
|
myocardial ischemia |
4 |
|
myocardial ischemia-reperfusion injury |
4 |
|
n-propyl caffeamide |
4 |
|
pharmacokinetics |
4 |
|
pkc-ε |
4 |
|
pkm2 |
4 |
|
postconditioning |
4 |
|
rats |
4 |
|
rats, sprague-dawley |
4 |
|
regulatory variant |
4 |
|
repeated non-invasive limb ischemic preconditioning |
4 |
|
selection - genetic |
4 |
|
stat3 |
4 |
|
variant prioritization |
4 |
|
ω-alkynyl arachidonic acid |
4 |
|
acute myocardial infarction |
3 |
|
adenosine |
3 |
|
allopurinol |
3 |
|
amp-activated protein kinase |
3 |
|
analgesics, opioid - administration & dosage |
3 |
|
analgesics, opioid - administration and dosage |
3 |
|
animal experiment |
3 |
|
apoptosis - drug effects |
3 |
|
arginine - pharmacology |
3 |
|
astrocyte |
3 |
|
biological effects |
3 |
|
c-jun n-terminal kinase |
3 |
|
cardiac biomarkers |
3 |
|
cardiac protection |
3 |
|
cardiovascular agents - administration & dosage |
3 |
|
cardiovascular diseases |
3 |
|
chronic post-ischemia pain |
3 |
|
controlled study |
3 |
|
coronary artery bypass graft surgery |
3 |
|
cxcl12 |
3 |
|
cxcl12/cxcr4 axis |
3 |
|
cxcr4 |
3 |
|
databases |
3 |
|
epigenetics |
3 |
|
forkhead box protein o1 |
3 |
|
foxo1 |
3 |
|
glial–glial crosstalk |
3 |
|
heart infarction size |
3 |
|
heart muscle ischemia |
3 |
|
heart-type fatty acid binding protein |
3 |
|
hemodynamics - drug effects |
3 |
|
infusions, parenteral |
3 |
|
injections, spinal |
3 |
|
intrathecal morphine |
3 |
|
ischaemia reperfusion injury |
3 |
|
ischemic postconditioning - methods |
3 |
|
ischemic preconditioning, myocardial |
3 |
|
ischemic preconditioning, myocardial - methods |
3 |
|
isoflurane |
3 |
|
isoflurane - therapeutic use |
3 |
|
l-arginine |
3 |
|
matrix metalloproteinase-2 |
3 |
|
mitochondria |
3 |
|
morphine - administration & dosage |
3 |
|
morphine - administration and dosage |
3 |
|
morphine - administration and dosage - metabolism |
3 |
|
myocardial infarction - metabolism - pathology - prevention & control |
3 |
|
myocardial injury |
3 |
|
myocardial ischemia-reperfusion |
3 |
|
myocardial reperfusion injury |
3 |
|
myocardial reperfusion injury - metabolism - pathology - prevention & control |
3 |
|
myocardial reperfusion injury - prevention and control |
3 |
|
myocardium - pathology |
3 |
|
narcotic antagonists - pharmacology |
3 |
|
neuroinflammation |
3 |
|
neuromodulator |
3 |
|
neuropathic pain |
3 |
|
nitrative stress |
3 |
|
nitrosative stress |
3 |
|
opioids |
3 |
|
oxidative stress - drug effects |
3 |
|
pathological pain |
3 |
|
post-ischemic myocardial injury |
3 |
|
preconditioning |
3 |
|
propofol - pharmacology |
3 |
|
propofol - therapeutic use |
3 |
|
rap1 |
3 |
|
receptors, opioid - agonists - metabolism |
3 |
|
receptors, opioid - drug effects - physiology |
3 |
|
receptors, opioid, delta - agonists |
3 |
|
receptors, opioid, kappa - agonists |
3 |
|
receptors, opioid, mu - agonists |
3 |
|
receptors, purinergic p1 - metabolism |
3 |
|
remote preconditioning |
3 |
|
reperfusion injury |
3 |
|
spinal cord |
3 |
|
spinal opioid receptors |
3 |
|
tumor necrosis factor-a |
3 |
|
tumor necrosis factor-alpha - pharmacology |
3 |
|
vascular remodeling |
3 |
|
15-f 2t-isoprostane |
2 |
|
acute respiratory distress syndrome |
2 |
|
adrenergic beta-antagonists - therapeutic use |
2 |
|
aged |
2 |
|
ampk |
2 |
|
anaesthetic conditioning |
2 |
|
analysis of variance |
2 |
|
anesthetics, inhalation - pharmacology |
2 |
|
anesthetics, intravenous - pharmacology |
2 |
|
angioplasty, balloon, coronary - methods |
2 |
|
antioxidant |
2 |
|
bilirubin |
2 |
|
biomarker |
2 |
|
blotting, western |
2 |
|
bosentan |
2 |
|
brahma-related gene 1 |
2 |
|
cancer |
2 |
|
cardiac aging |
2 |
|
cardiac hypertrophy |
2 |
|
cardiac ischemia |
2 |
|
cardiac preconditioning |
2 |
|
cardiomyocytes |
2 |
|
cardiomyopathy |
2 |
|
cardiopulmonary bypass |
2 |
|
cardiotonic agents |
2 |
|
caveolin 1 |
2 |
|
caveolin 3 |
2 |
|
cell proliferation |
2 |
|
cell survival - drug effects |
2 |
|
cells, cultured |
2 |
|
ceramides - biosynthesis |
2 |
|
comparative proteomics |
2 |
|
connexin |
2 |
|
coronary artery bypass |
2 |
|
coronavirus |
2 |
|
covid-19 |
2 |
|
creatine kinase - metabolism |
2 |
|
cyp1 gene |
2 |
|
disinfection by-products |
2 |
|
drug administration schedule |
2 |
|
elderly patients |
2 |
|
electron transport chain |
2 |
|
endothelial cells - drug effects - physiology |
2 |
|
endothelial nitric oxide synthase |
2 |
|
endothelin-1 antagonist |
2 |
|
energy homeostasis |
2 |
|
enzyme activation |
2 |
|
enzyme inhibitors - therapeutic use |
2 |
|
enzyme-linked immunosorbent assay |
2 |
|
fatty acid metabolism |
2 |
|
female |
2 |
|
ferroptosis |
2 |
|
foxo |
2 |
|
free radical scavengers |
2 |
|
gap junction |
2 |
|
glucagon-like peptide 1-receptor agonists |
2 |
|
glutathione peroxidase - metabolism |
2 |
|
heart - drug effects - physiopathology |
2 |
|
high-flow nasal cannula therapy |
2 |
|
human umbilical vein endothelial cells |
2 |
|
hydrogen peroxide - metabolism |
2 |
|
inducible no synthase (inos) |
2 |
|
inflammation |
2 |
|
insulin signal pathway |
2 |
|
intestinal mucosa - metabolism - pathology - ultrastructure |
2 |
|
intraoperative period |
2 |
|
ischaemia-reperfusion injury |
2 |
|
ischaemia/reperfusion |
2 |
|
ischaemic conditioning |
2 |
|
ischemia reperfusion |
2 |
|
ischemia-reperfusion |
2 |
|
ischemia-reperfusion (i/r) injury |
2 |
|
ischemia/reperfusion injury |
2 |
|
ischemic heart disease |
2 |
|
ischemic post-conditioning |
2 |
|
isoprostanes - blood |
2 |
|
isoprostanes - pharmacology |
2 |
|
kidney injury |
2 |
|
lipid peroxidation |
2 |
|
malondialdehyde - analysis |
2 |
|
metabolism |
2 |
|
metformin |
2 |
|
microscopy, electron, transmission |
2 |
|
mitochondrial atp-sensitive potassium channel (mitokatp) |
2 |
|
mitochondrial-dependent apoptosis |
2 |
|
myocardial infarction - pathology - prevention & control |
2 |
|
myocardial reperfusion injury - metabolism - physiopathology |
2 |
|
myocardial reperfusion injury - physiopathology - prevention and control |
2 |
|
nature organic matter |
2 |
|
nitric oxide |
2 |
|
nrk52e cells |
2 |
|
nuclear factor-erythroid-2-related factor-2 |
2 |
|
oxidative metabolism |
2 |
|
p53 |
2 |
|
peroxynitrite |
2 |
|
phthalimides - pharmacology |
2 |
|
pneumonia |
2 |
|
pparα |
2 |
|
pparα modulator |
2 |
|
probability |
2 |
|
prognosis |
2 |
|
propanolamines - therapeutic use |
2 |
|
protein kinase c - physiology |
2 |
|
protein kinase c β2 |
2 |
|
pterostilbene |
2 |
|
rabbits |
2 |
|
random allocation |
2 |
|
rats, wistar |
2 |
|
reactive oxygen species |
2 |
|
reactive oxygen species - metabolism |
2 |
|
reperfusion injury - drug therapy - metabolism - pathology |
2 |
|
reperfusion injury - prevention & control |
2 |
|
review |
2 |
|
rna, messenger - analysis |
2 |
|
sars-cov-2 |
2 |
|
sensitivity and specificity |
2 |
|
sevoflurane |
2 |
|
signal transduction |
2 |
|
sodium–glucose co-transporter type 2 inhibitors |
2 |
|
sphingomyelin phosphodiesterase - genetics |
2 |
|
stattic |
2 |
|
streptozotocin |
2 |
|
sulfonamides - pharmacology |
2 |
|
superoxide dismutase - metabolism |
2 |
|
telomere |
2 |
|
transcriptomics |
2 |
|
tumor necrosis factor β |
2 |
|
vascular endothelial cells |
2 |
|
vascular endothelial growth factor |
2 |
|
15-f2t-isoprostane |
1 |
|
6-ketoprostaglandin f1 alpha - blood |
1 |
|
abdominal muscles |
1 |
|
acetaldehyde |
1 |
|
acetaldehyde - pharmacology |
1 |
|
acetyl-coa carboxylase - blood - metabolism |
1 |
|
acetylcysteine - metabolism - pharmacology |
1 |
|
acetylcysteine - pharmacology |
1 |
|
acetylcysteine - therapeutic use |
1 |
|
acrylic acid |
1 |
|
acupuncture |
1 |
|
acute lung injury |
1 |
|
acute lung injury (ali) |
1 |
|
acute stress |
1 |
|
adenosine a3 receptor |
1 |
|
adiponectin - blood - metabolism |
1 |
|
adolescent |
1 |
|
adult |
1 |
|
aging |
1 |
|
aging - physiology |
1 |
|
akt |
1 |
|
aldehyde reductase - physiology |
1 |
|
aldose reductase |
1 |
|
amidines - pharmacology |
1 |
|
amine oxidase (copper-containing) - blood |
1 |
|
amp-activated protein kinases |
1 |
|
anesthetics - therapeutic use |
1 |
|
anesthetics, inhalation - therapeutic use |
1 |
|
anesthetics, intravenous - administration & dosage - pharmacology |
1 |
|
angiotensin ii |
1 |
|
angiotensin ii - pharmacology |
1 |
|
angiotensins |
1 |
|
animal cell |
1 |
|
animal model |
1 |
|
animal proteomics |
1 |
|
animal tissue |
1 |
|
animals, newborn |
1 |
|
anti-inflammation |
1 |
|
antioxidant capacity |
1 |
|
antioxidant status |
1 |
|
antioxidants - administration & dosage |
1 |
|
antioxidants - administration & dosage - pharmacology - therapeutic use |
1 |
|
antioxidants - adverse effects |
1 |
|
antioxidants - metabolism |
1 |
|
antioxidants - metabolism - therapeutic use |
1 |
|
antioxidants - pharmacology |
1 |
|
antioxidants - therapeutic use |
1 |
|
aorta |
1 |
|
aorta - physiopathology |
1 |
|
aorta - surgery |
1 |
|
apoptotic injury |
1 |
|
area under the curve |
1 |
|
arrhythmias, cardiac - metabolism - physiopathology |
1 |
|
arterial blood pressure |
1 |
|
arterial smooth muscle cells |
1 |
|
arteries |
1 |
|
asymptomatic disease |
1 |
|
atg5 |
1 |
|
attitudes |
1 |
|
attribution |
1 |
|
autophagosome |
1 |
|
back-flow |
1 |
|
bcl-2-associated x protein |
1 |
|
bcl-2-associated x protein - metabolism |
1 |
|
benzylamines - pharmacology |
1 |
|
biological assay |
1 |
|
biological markers - blood |
1 |
|
biological markers - metabolism |
1 |
|
blame |
1 |
|
bland white garland syndrome |
1 |
|
blood gas analysis |
1 |
|
blood glucose |
1 |
|
blood glucose - drug effects - metabolism |
1 |
|
blood glucose - metabolism |
1 |
|
blood pressure |
1 |
|
blood pressure - drug effects |
1 |
|
blood pressure - drug effects - physiology |
1 |
|
blood pressure - physiology |
1 |
|
bronchoalveolar lavage fluid - chemistry |
1 |
|
bupivacaine |
1 |
|
bv-2 cell line |
1 |
|
calcium/calmodulin-dependent protein kinase ii |
1 |
|
camk2α |
1 |
|
cancer care |
1 |
|
capsaicin |
1 |
|
carboxypeptidase a |
1 |
|
cardiac contractility |
1 |
|
cardiac function |
1 |
|
cardiac output - physiology |
1 |
|
cardiac output, low - blood |
1 |
|
cardiac output, low - physiopathology - therapy |
1 |
|
cardiac pulmonary bypass |
1 |
|
cardiac surgical procedures |
1 |
|
cardiac surgical procedures - methods |
1 |
|
cardiac volume - physiology |
1 |
|
cardiomegaly - enzymology - pathology - prevention & control |
1 |
|
cardiomyocyte |
1 |
|
cardiopulmonary bypass - adverse effects |
1 |
|
cardiopulmonary bypass - adverse effects - methods |
1 |
|
cardiovascular abnormalities |
1 |
|
cathepsin s |
1 |
|
cell death |
1 |
|
cell size - drug effects |
1 |
|
cerebral hypoperfusion |
1 |
|
cerebral vasospasm |
1 |
|
cerebrovascular circulation - drug effects - physiology |
1 |
|
chemotherapy, adjuvant |
1 |
|
child |
1 |
|
child, preschool |
1 |
|
chinese nurses |
1 |
|
cholesterol - blood |
1 |
|
chronic disease |
1 |
|
cisatracurium |
1 |
|
clinical feature |
1 |
|
cognitive function |
1 |
|
collagen type i - analysis |
1 |
|
collagen type ii - analysis |
1 |
|
computer assisted tomography |
1 |
|
conditioning (psychology) |
1 |
|
confidence intervals |
1 |
|
congenital heart disease |
1 |
|
connective tissue growth factor |
1 |
|
connexin 43 |
1 |
|
copper/zinc superoxide dismutase |
1 |
|
coronary artery bypass - adverse effects |
1 |
|
coronary circulation - physiology |
1 |
|
coronary vessels - physiopathology |
1 |
|
coronavirus disease |
1 |
|
creatine kinase - blood |
1 |
|
creatine kinase, mb form |
1 |
|
cyclic strain |
1 |
|
cyclooxygenase 2 - metabolism |
1 |
|
cytokines - blood |
1 |
|
deferoxamine |
1 |
|
degranulation |
1 |
|
densely connected convolutional networks |
1 |
|
dexmedetomidine |
1 |
|
diabetes mellitus - metabolism |
1 |
|
diabetes mellitus, experimental - blood - physiopathology |
1 |
|
diabetes mellitus, experimental - drug therapy - metabolism - pathology |
1 |
|
diabetes mellitus, experimental - drug therapy - pathology |
1 |
|
diabetes mellitus, experimental - enzymology |
1 |
|
diabetes mellitus, experimental - enzymology - pathology |
1 |
|
diabetes mellitus, experimental - enzymology - physiopathology |
1 |
|
diabetes mellitus, experimental - immunology - metabolism |
1 |
|
diabetes mellitus, experimental - metabolism |
1 |
|
diabetes mellitus, experimental - metabolism - physiopathology |
1 |
|
diabetes mellitus, experimental - metabolism - prevention & control |
1 |
|
diabetes mellitus, experimental - physiopathology |
1 |
|
diabetes mellitus, type 2 - chemically induced - metabolism |
1 |
|
diabetes mellitus, type 2 - enzymology |
1 |
|
diabetic |
1 |
|
diabetic myocardium |
1 |
|
diabetic rats |
1 |
|
diabetic retinopathy |
1 |
|
diabetic retinopathy - drug therapy - metabolism - pathology |
1 |
|
diastole - drug effects - physiology |
1 |
|
dietary fats - pharmacology |
1 |
|
differentially expressed genes |
1 |
|
dinoprost - analogs & derivatives |
1 |
|
dinoprost - analogs & derivatives - analysis - blood |
1 |
|
dinoprost - analogs & derivatives - blood |
1 |
|
dinoprost - analogs & derivatives - blood - metabolism |
1 |
|
dinoprost - analogs & derivatives - metabolism |
1 |
|
dinoprost - analogs & derivatives - pharmacology |
1 |
|
disease susceptibility |
1 |
|
dobutamine - pharmacology |
1 |
|
dorsal root ganglion |
1 |
|
double-blind method |
1 |
|
down-regulation - drug effects - physiology |
1 |
|
drug evaluation, preclinical |
1 |
|
drug synergism |
1 |
|
drugs, chinese herbal - administration & dosage - pharmacology - therapeutic use |
1 |
|
drugs, chinese herbal - pharmacology |
1 |
|
drugs, chinese herbal - pharmacology - therapeutic use |
1 |
|
dysferlin |
1 |
|
egr-1 |
1 |
|
endogenous |
1 |
|
endothelial cells - drug effects - metabolism - pathology |
1 |
|
endothelial cells - drug effects - ultrastructure |
1 |
|
endothelin-1 |
1 |
|
endothelin-1 (et-1) |
1 |
|
endothelin-1 - analysis |
1 |
|
endothelin-1 - antagonists & inhibitors |
1 |
|
endothelin-1 - biosynthesis |
1 |
|
endothelin-1 - blood |
1 |
|
endothelin-1 - metabolism |
1 |
|
endothelins - blood |
1 |
|
endothelium |
1 |
|
endothelium, vascular - metabolism - pathology |
1 |
|
endothelium, vascular - physiology |
1 |
|
energy transfer |
1 |
|
enos |
1 |
|
enzyme inhibitors - pharmacology |
1 |
|
epoprostenol - blood |
1 |
|
equipment design |
1 |
|
equipment failure |
1 |
|
ers |
1 |
|
ethanol |
1 |
|
ethanol - administration and dosage |
1 |
|
extracellular signal-regulated kinase 1/2 |
1 |
|
extremities - blood supply - physiopathology |
1 |
|
f2-isoprostanes - biosynthesis |
1 |
|
f2-isoprostanes - blood |
1 |
|
feature extraction technology |
1 |
|
fluorescent antibody technique, indirect |
1 |
|
free radical scavengers - administration & dosage - therapeutic use |
1 |
|
free radical scavengers - pharmacology |
1 |
|
free radical scavengers - therapeutic use |
1 |
|
free radicals |
1 |
|
free radicals - metabolism |
1 |
|
fructose |
1 |
|
gaba(a)r α |
1 |
|
gastric mucosa - drug effects |
1 |
|
gastrointestinal agents - pharmacology - therapeutic use |
1 |
|
gastrointestinal diseases - blood - etiology - prevention & control |
1 |
|
gene expression |
1 |
|
gene expression regulation - drug effects |
1 |
|
genes, bcl-2 - genetics - physiology |
1 |
|
glioblastoma |
1 |
|
glucose - administration & dosage - pharmacology |
1 |
|
glucose - metabolism |
1 |
|
glucose - pharmacology |
1 |
|
glucose tolerance test |
1 |
|
glucose transporter type 4 - metabolism |
1 |
|
glutathione peroxidase 4 |
1 |
|
glycogen - biosynthesis |
1 |
|
haeme oxygenase-1 |
1 |
|
halothane - therapeutic use |
1 |
|
heart |
1 |
|
heart - drug effects |
1 |
|
heart - drug effects - physiology |
1 |
|
heart - physiology |
1 |
|
heart - physiopathology |
1 |
|
heart defects, congenital - blood - surgery |
1 |
|
heart defects, congenital - diagnosis - drug therapy - surgery |
1 |
|
heart diseases - drug therapy - pathology |
1 |
|
heart failure |
1 |
|
heart function tests |
1 |
|
heart protection |
1 |
|
heart rate - drug effects |
1 |
|
heart septal defects - blood - surgery |
1 |
|
heart surgery |
1 |
|
heart valve prosthesis implantation |
1 |
|
heart ventricles - enzymology - immunology - pathology |
1 |
|
heart-assist devices |
1 |
|
heme oxygenase (decyclizing) - immunology - metabolism |
1 |
|
heme oxygenase (decyclizing) - metabolism |
1 |
|
heme oxygenase 1 |
1 |
|
heme oxygenase-1 - antagonists and inhibitors - physiology |
1 |
|
heme oxygenase-1 - metabolism |
1 |
|
hemin - therapeutic use |
1 |
|
hemodilution |
1 |
|
hemodynamics |
1 |
|
hemodynamics - drug effects - physiology |
1 |
|
hemodynamics - physiology |
1 |
|
hemoperfusion |
1 |
|
hemorrhagic |
1 |
|
hepatic ischaemia/reperfusion |
1 |
|
hepatic stellate cells |
1 |
|
hepatic stellate cells - drug effects - metabolism |
1 |
|
hepatocytes - drug effects - metabolism |
1 |
|
hindlimb |
1 |
|
hippocampus |
1 |
|
ho-1 |
1 |
|
hydrogen peroxide |
1 |
|
hydrogen peroxide - pharmacology |
1 |
|
hydrogen-ion concentration - drug effects |
1 |
|
hyperalgesia |
1 |
|
hyperoxia acute lung injury |
1 |
|
hypertension - chemically induced - metabolism - physiopathology |
1 |
|
hypertonic sodium chloride hydroxyethyl starch solution |
1 |
|
hypertrophy - chemically induced - prevention & control |
1 |
|
hypnotics and sedatives - pharmacology |
1 |
|
hypoglycemic agents - pharmacology |
1 |
|
hypoxia-reoxygenation injury |
1 |
|
hypoxia/reoxygenation |
1 |
|
iliac artery - physiology |
1 |
|
imidazoles - pharmacology |
1 |
|
immediate-early proteins - metabolism |
1 |
|
immunoenzyme techniques |
1 |
|
immunohistochemistry |
1 |
|
in situ nick-end labeling |
1 |
|
incubation period |
1 |
|
indole-3-carbinol |
1 |
|
indoles - pharmacology |
1 |
|
inducible haeme oxygenase |
1 |
|
inducible nitric oxide synthase |
1 |
|
inflammation - metabolism - pathology |
1 |
|
infusions, intravenous |
1 |
|
insulin - blood |
1 |
|
insulin - metabolism |
1 |
|
insulin - pharmacology |
1 |
|
insulin resistance - physiology |
1 |
|
insulin sensitivity |
1 |
|
intercellular signaling peptides and proteins - metabolism |
1 |
|
interleukin-6 - biosynthesis |
1 |
|
interleukin-6 - blood |
1 |
|
interleukin-6 - metabolism |
1 |
|
intestinal ischemia reperfusion |
1 |
|
intestinal mucosa - blood supply - metabolism - pathology |
1 |
|
intestinal mucosa - drug effects - pathology - ultrastructure |
1 |
|
intestinal mucosa - immunology - metabolism - pathology |
1 |
|
intestinal reperfusion injury |
1 |
|
intestine |
1 |
|
intestine, small - blood supply - metabolism |
1 |
|
intestines - blood supply - injuries - metabolism |
1 |
|
intra-operative blood loss |
1 |
|
intra-operative haemoglobin loss |
1 |
|
inverted emulsion polymerization |
1 |
|
ischaemic post-conditioning |
1 |
|
ischemia |
1 |
|
ischemia - physiopathology |
1 |
|
ischemia-reperfusion injury |
1 |
|
ischemic postconditioning |
1 |
|
ischemic preconditioning |
1 |
|
ischemic preconditioning - methods |
1 |
|
isoenzymes - blood |
1 |
|
isoenzymes - metabolism |
1 |
|
isoflurane - analogs & derivatives - pharmacology |
1 |
|
isoprostane |
1 |
|
isoprostanes - metabolism |
1 |
|
itraq |
1 |
|
jak/stat3 |
1 |
|
l-lactate dehydrogenase - metabolism |
1 |
|
lactic acid - analysis |
1 |
|
laparoscopy |
1 |
|
left ventricular end-diastolic diameter z-score |
1 |
|
leucine - metabolism |
1 |
|
lipopolysaccharide |
1 |
|
lipopolysaccharides |
1 |
|
lipopolysaccharides - blood |
1 |
|
liver - drug effects - metabolism - physiology |
1 |
|
liver diseases, alcoholic - enzymology - metabolism - pathology - prevention and control |
1 |
|
liver glycogen - biosynthesis |
1 |
|
liver transplantation |
1 |
|
local anesthetic |
1 |
|
lung |
1 |
|
lung - blood supply |
1 |
|
lung - blood supply - physiopathology |
1 |
|
lung - pathology |
1 |
|
lung injury |
1 |
|
lung ischemia reperfusion |
1 |
|
lung surfactant protein |
1 |
|
macrophages - metabolism - pathology |
1 |
|
malondialdehyde - blood |
1 |
|
malondialdehyde - metabolism |
1 |
|
manganese superoxide dismutase |
1 |
|
mast cell |
1 |
|
mcu |
1 |
|
mechanical ventilation |
1 |
|
medical staff safety |
1 |
|
methoxamine - pharmacology |
1 |
|
methyl ethers - pharmacology |
1 |
|
methylprednisolone |
1 |
|
methylprednisolone - pharmacology |
1 |
|
microcirculation - drug effects - metabolism |
1 |
|
microglia |
1 |
|
microglia - metabolism - pathology |
1 |
|
microglial polarization |
1 |
|
middle aged |
1 |
|
mitochondrial fusion and fission |
1 |
|
mitochondrial oxidative stress |
1 |
|
mitsugumin-53 |
1 |
|
models, animal |
1 |
|
mortality |
1 |
|
multienzyme complexes - metabolism |
1 |
|
multivariate analysis |
1 |
|
muscle, skeletal - drug effects - enzymology |
1 |
|
muscle, skeletal - drug effects - enzymology - metabolism - physiology |
1 |
|
myeloid differentiation protein-2 (md-2) |
1 |
|
myocardial contraction - drug effects |
1 |
|
myocardial contraction - physiology |
1 |
|
myocardial dysfunction |
1 |
|
myocardial hypertrophy |
1 |
|
myocardial infarction - metabolism - pathology - physiopathology |
1 |
|
myocardial infarction - metabolism - pathology - physiopathology - prevention & control |
1 |
|
myocardial infarction - metabolism - physiopathology |
1 |
|
myocardial infarction - prevention & control |
1 |
|
myocardial ischaemia reperfusion injury |
1 |
|
myocardial ischemia - complications |
1 |
|
myocardial ischemia - complications - physiopathology |
1 |
|
myocardial ischemia - drug therapy - metabolism |
1 |
|
myocardial ischemia - metabolism |
1 |
|
myocardial ischemia - metabolism - physiopathology - prevention & control |
1 |
|
myocardial ischemia - physiopathology |
1 |
|
myocardial ischemia reperfusion |
1 |
|
myocardial ischemia‐reperfusion injury |
1 |
|
myocardial reperfusion |
1 |
|
myocardial reperfusion injury - blood - drug therapy |
1 |
|
myocardial reperfusion injury - drug therapy - metabolism - pathology - physiopathology |
1 |
|
myocardial reperfusion injury - etiology - prevention & control |
1 |
|
myocardial reperfusion injury - metabolism |
1 |
|
myocardial reperfusion injury - metabolism - pathology - physiopathology |
1 |
|
myocardial reperfusion injury - metabolism - physiopathology - prevention & control |
1 |
|
myocardial reperfusion injury - metabolism - prevention & control |
1 |
|
myocardial reperfusion injury - prevention & control |
1 |
|
myocardium |
1 |
|
myocardium - chemistry - enzymology |
1 |
|
myocardium - enzymology |
1 |
|
myocardium - enzymology - immunology - pathology |
1 |
|
myocardium - metabolism |
1 |
|
myocardium - metabolism - pathology |
1 |
|
myocardium/en |
1 |
|
myocytes, cardiac - drug effects - metabolism - pathology |
1 |
|
myocytes, cardiac - drug effects - pathology |
1 |
|
myosin heavy chain |
1 |
|
myosin heavy chains - genetics - metabolism |
1 |
|
n,n'-dihydroxyethylacrylamide |
1 |
|
n-acetylcysteine |
1 |
|
n-methyl-d-aspartate |
1 |
|
nadph oxidase |
1 |
|
nadph oxidase - metabolism |
1 |
|
nerve block |
1 |
|
neurotensin - physiology |
1 |
|
neurotoxicity |
1 |
|
neutrophils - metabolism |
1 |
|
nf-κb |
1 |
|
ng-nitroarginine methyl ester - pharmacology |
1 |
|
nicotinamide adenine dinucleotide phosphate oxidase |
1 |
|
nitrates - blood |
1 |
|
nitrates - blood - metabolism - physiology |
1 |
|
nitric oxide - analysis - metabolism |
1 |
|
nitric oxide - biosynthesis - physiology |
1 |
|
nitric oxide - metabolism |
1 |
|
nitric oxide donors - therapeutic use |
1 |
|
nitric oxide synthase - analysis |
1 |
|
nitric oxide synthase type ii |
1 |
|
nitric oxide synthase type ii - metabolism |
1 |
|
nitric oxide synthase type iii |
1 |
|
nitric oxide synthase type iii - metabolism |
1 |
|
nitric oxide synthase type iii - physiology |
1 |
|
nitrites - blood |
1 |
|
nitroprusside - therapeutic use |
1 |
|
nitrotyrosine |
1 |
|
nitrous oxide - therapeutic use |
1 |
|
nlrp3 inflammasome |
1 |
|
nox2 |
1 |
|
nucleotide‐binding oligomerization domain‐like receptor protein 3 inflammasome |
1 |
|
oncology |
1 |
|
organ size |
1 |
|
orthotopic liver transplantation |
1 |
|
oxidants - pharmacology |
1 |
|
oxidative injury |
1 |
|
oxidative stress - drug effects - physiology |
1 |
|
oxidative stress - physiology |
1 |
|
oxygen - blood |
1 |
|
paediatric surgery |
1 |
|
partial pressure |
1 |
|
perfusion |
1 |
|
pericyte |
1 |
|
pericytes - metabolism - pathology |
1 |
|
personal protective equipment |
1 |
|
phosphatase and tensin homologue deleted on chromosome 10 (pten) |
1 |
|
phosphatidylinositol 3-kinase - antagonists & inhibitors |
1 |
|
phosphatidylinositol 3-kinases - metabolism |
1 |
|
phosphatidylinositol-dependent kinase 1 |
1 |
|
phosphoproteins - metabolism |
1 |
|
phosphorylation |
1 |
|
phytotherapy - methods |
1 |
|
pi3k |
1 |
|
plant extracts |
1 |
|
plants, medicinal |
1 |
|
post-conditioning |
1 |
|
postoperative care |
1 |
|
postoperative complications |
1 |
|
postoperative complications - prevention & control |
1 |
|
precision-cut liver slice |
1 |
|
pro-inflammatory cytokines |
1 |
|
programmed cell death |
1 |
|
proinflammatory cytokines |
1 |
|
prolonged duration of inotrope support |
1 |
|
prolonged mechanical ventilation |
1 |
|
propofol - administration & dosage |
1 |
|
propofol - administration & dosage - pharmacology |
1 |
|
propofol - administration & dosage - therapeutic use |
1 |
|
propofol - metabolism - therapeutic use |
1 |
|
prospective studies |
1 |
|
protein isoforms - genetics - metabolism |
1 |
|
protein kinase b |
1 |
|
protein kinase c |
1 |
|
protein kinase c - metabolism |
1 |
|
protein kinase c β 2 |
1 |
|
protein kinase c ζ |
1 |
|
protein transduction domain |
1 |
|
protein transport |
1 |
|
protein tyrosine phosphatase, non-receptor type 1 |
1 |
|
protein tyrosine phosphatases - biosynthesis |
1 |
|
protein-serine-threonine kinases - metabolism |
1 |
|
proteins - metabolism |
1 |
|
proteome - metabolism |
1 |
|
proteomic |
1 |
|
proto-oncogene proteins c-akt - metabolism |
1 |
|
proto-oncogene proteins c-bcl-2 - genetics - physiology |
1 |
|
proto-oncogene proteins c-bcl-2 - metabolism |
1 |
|
pten |
1 |
|
ptp1b |
1 |
|
rat |
1 |
|
receptor, endothelin a - antagonists & inhibitors |
1 |
|
receptor, endothelin b - antagonists & inhibitors |
1 |
|
receptors, endothelin - antagonists & inhibitors |
1 |
|
receptors, thromboxane - metabolism |
1 |
|
reference values |
1 |
|
regional anesthesia |
1 |
|
remote ischaemic preconditioning |
1 |
|
remote ischemic postconditioning |
1 |
|
remote limb ischaemic postconditioning |
1 |
|
repeated non-invasive limb ischemic pre-conditioning |
1 |
|
reperfusion |
1 |
|
reperfusion - methods |
1 |
|
reperfusion injury - blood - metabolism |
1 |
|
reperfusion injury - drug therapy - physiopathology |
1 |
|
reperfusion injury - immunology - pathology - prevention and control |
1 |
|
reperfusion injury - metabolism - pathology |
1 |
|
reperfusion injury - metabolism - prevention & control |
1 |
|
reperfusion injury - prevention and control |
1 |
|
resolvin d1 |
1 |
|
respiratory distress syndrome, adult - chemically induced - metabolism - pathology - prevention & control |
1 |
|
retina - drug effects - metabolism |
1 |
|
retrospective studies |
1 |
|
risk factors |
1 |
|
rna interference (rnai) |
1 |
|
rna sequencing |
1 |
|
rna, messenger - metabolism |
1 |
|
rosiglitazone |
1 |
|
salvia miltiorrhiza |
1 |
|
self-resolution |
1 |
|
sepsis |
1 |
|
serpin protease inhibitor b1 |
1 |
|
severity of illness index |
1 |
|
sevoflurane postconditioning |
1 |
|
sex difference |
1 |
|
shear stress |
1 |
|
sheep |
1 |
|
shock |
1 |
|
shock, hemorrhagic - drug therapy - physiopathology |
1 |
|
signal transduction - drug effects |
1 |
|
skeletal muscle |
1 |
|
small intestinal ischemia |
1 |
|
smoking - adverse effects |
1 |
|
sodium nitroprusside |
1 |
|
sq-29548 |
1 |
|
stat3 transcription factor - metabolism |
1 |
|
streptozocin - administration & dosage |
1 |
|
streptozocin - toxicity |
1 |
|
streptozotocin-induced diabetes |
1 |
|
stress response |
1 |
|
stress, physiological - physiopathology |
1 |
|
stroke volume - physiology |
1 |
|
subarachnoid hemorrhage |
1 |
|
sulfonamides - administration & dosage - pharmacology |
1 |
|
super water-absorbent resin |
1 |
|
superoxide dismutase |
1 |
|
superoxide dismutase - blood |
1 |
|
superoxide dismutase - genetics - metabolism |
1 |
|
superoxides - analysis |
1 |
|
surface properties |
1 |
|
surgery |
1 |
|
survival rate |
1 |
|
swine |
1 |
|
systemic inflammatory response syndrome - prevention & control |
1 |
|
systemic ischemic preconditioning |
1 |
|
temozolomide |
1 |
|
tert-butylhydroperoxide - pharmacology |
1 |
|
tetralogy of fallot |
1 |
|
thiazolidinediones - pharmacology |
1 |
|
thiobarbituric acid reactive substances - analysis |
1 |
|
thiobarbituric acid reactive substances - metabolism |
1 |
|
thromboxane (txa2) |
1 |
|
thromboxane a2 - metabolism |
1 |
|
thromboxane b2 - blood |
1 |
|
thromboxane-a synthase - antagonists & inhibitors |
1 |
|
thymine - metabolism |
1 |
|
thyroid hormone |
1 |
|
time factors |
1 |
|
topk |
1 |
|
training methods |
1 |
|
tramadol |
1 |
|
translocation |
1 |
|
treatment outcome |
1 |
|
triglycerides - blood |
1 |
|
triiodothyronine - pharmacology |
1 |
|
trpv1 |
1 |
|
tumor necrosis factor-alpha |
1 |
|
tumor necrosis factor-alpha - antagonists & inhibitors - pharmacology |
1 |
|
tumor necrosis factor-alpha - biosynthesis |
1 |
|
tumor necrosis factor-alpha - blood |
1 |
|
tumor necrosis factor-alpha - toxicity |
1 |
|
type 2 diabetes |
1 |
|
type ii |
1 |
|
tyrosine - analogs & derivatives - analysis |
1 |
|
tyrosine - analogs & derivatives - biosynthesis |
1 |
|
umbilical veins - cytology - drug effects |
1 |
|
vascular diseases - physiopathology |
1 |
|
vascular resistance - physiology |
1 |
|
vasoconstrictor agents - blood |
1 |
|
vasoconstrictor agents - pharmacology |
1 |
|
ventricular assist device |
1 |
|
ventricular function, left - drug effects |
1 |
|
ventricular function, left - physiology |
1 |
|
ventricular pressure - drug effects |
1 |
|
ventricular pressure - physiology |
1 |
|
xanthine oxidase |
1 |
|
xanthine oxidase - metabolism |
1 |
|
yap/taz |
1 |
